Stephen Mandel Fate Therapeutics Inc Transaction History

Lone Pine Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $105 Million - $142 Million	-2,199,284 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $26.7 Million - $43.1 Million	450,000 Added 25.72%	2,199,284 $130 Million
Q1 2021 May 18, 2021	BUY	$72.16 - $117.4 $62.5 Million - $102 Million	865,618 Added 97.96%	1,749,284 $144 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $33.7 Million - $89.2 Million	883,666 New	883,666 $80.4 Million

178

124M

222K

48.6K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $318M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Lone Pine Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Lone Pine Capital LLC and Stephen Mandel with notifications on news.